干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现


共找到14条结果
排序:

简介: NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that a U.S. Food and Drug Administration (FDA) investigational new drug application (IND) is open for its multicenter Phase III study for the treatment of pediatric HSCT-TMA with nomacopan, allowing clinical sites to
简介: 4月23日,Communications Biology 在线发表了中国科学院分子植物科学卓越创新中心/植物生理生态研究所分子遗传国家重点实验室肖晗研究组题为Domain-specific expression of meristematic genes is defined by the LITTLE ZIPPER protein DTM in tomato 的研究,该研究揭示了番茄分生组织发育调控的新机制。番茄是重要的园艺作物和果实发育的模式植物。野生番茄果实只有普通葡萄大小(1-2厘米),经过长期的人类驯化和育种改良后,番茄增大了数十至上百倍。由于植物地上部分的细胞来源于茎尖分生组织或其转化而来的侧生分生组织和花分生组织,果实大小与茎尖分生组织(SAM)发育密不可分。研究表明,茎尖分生组织(SAM)的发育依赖CLAVATA (CLV)-WUSCHEL (WUS)途径来维持其干细胞活性。该研究报道了一个从EMS诱变群体中鉴定到的分生组织发育异常突变体dtm-1(defective tomato meristems -1)。dtm-1突变体茎扁大扭曲,叶序、花和果实的发育也受到严重影
简介: The FDA continued on a tear in the fourth quarter, approving some 20 new products and 4 biosimilars. Among the green lights are the first drug approval for any tumor with a specific gene fusion and the first new flu drug in 20 years. Two decisions on gene therapies, one in the United States and one in the European Union, are coming up. The first clinical trial for a phage cocktail in a topical burn application failed; it reduced bacterial loads, but less than the standard-of-care antibiotic.
简介: Treatment for dendritic cell neoplasm uses a diphtheria toxin payload to destroy cancer cells.The US Food and Drug Administration granted marketing authorization late last year to Elzonris (tagraxofusp) as an immunotoxin treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking the first time a drug has won approval for this rare blood cancer and the first regulatory go-ahead in a crowded field of biological therapies directed against CD123, an interleukin-3 (IL-3) receptor sub
简介: Researchers from The University of Texas Medical Branch at Galveston have developed a promising drug that has proven to significantly increase muscle size, strength and metabolic state in aged mice, according to a study just published in Biochemical Pharmacology.As we age, our bodies increasingly lose the ability to repair and rebuild degenerating skeletal muscles. Beginning around age 35, muscle mass, strength and function continually decline as we get older. This can dramatically limit the abi
简介: 追求尽善尽美Gibco StemFlex 细胞培养基支持无滋养层多能干细胞(PSC)的稳定扩增,经过优化可支持单细胞传代、基因编辑和重编程等新型应用。性能卓越—细胞存活率比mTeSR1更高维持FGF2活性—更长久且稳定地维持多能性,并且无需周末换液试剂选择广—可在最合适您当前应用的基质和传代试剂之间切换Superior performance in today’s modern applicationsFaster recovery following gene editingSuperior clonal expansion following single-cell passagingImproved reprogramming workflow and robust colony formationRobust support of PSC cultures during expansion and maintenanceThe newest feeder-free medium from Gibco brand, StemFlex Medium, is the only med
简介: NK cells, or natural killer cells, play an important role in the body's defences against cancer and various infections. Now, in a joint project, researchers at Lund University in Sweden, the University of Oxford and Karolinska Institutet in Stockholm have mapped how the different steps of the maturation process of these supercells from blood producing stem cells in the bone marrow are regulated: knowledge which is crucial for the development of new immunotherapies against cancer.Within the immun
简介: The TaqMan® OpenArray® Human Stem Cell Panel isan efficient, easy-to-use OpenArray® plate for the characterization of undifferentiatedstem cells or their differentiated derivatives. This gene signature paneltargets 609 well-defined genes validated as markers for pluripotency, plus 22endogenous control genes. The format of the OpenArray® plate allows for 1–4replicates to be run in parallel per plate. The TaqMan® OpenArray® Human Stem Cell Panel contains awell-defined
简介: Novartis is expanding its push into radiotherapeutics. In October, the drug giant struck a $2.1 billion deal to acquire Endocyte, the maker of a late-stage candidate for prostate cancer that combines the tissue-killing power of radiation with a small molecule that binds preferentially to tumor cells. And less than a year ago, Novartis paid $3.9 billion to get hold of Lutathera (lutetium Lu 177 dotatate), a first-in-class peptide-based radionuclide therapy and the first approved by the US regulat
发布时间